Condition: Metastatic Castration-Resistant Prostate Carcinoma · Metastatic Prostate Adenocarcinoma · Stage IVB Prostate Cancer AJCC v8 · Sponsor: Alliance for Clinical Trials in Oncology
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard way this medication is given. This study is for patients with hormone resistant prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body. Hormone resistant prostate cancer often has many cells containing a protein called prostate-specific membrane antigen (PSMA) on their surface. The normal cells in the prostate do not normally express as much PSMA protein on their surface as cancer cells. Lutetium 177 Lu PSMA RLT binds to the PSMA protein on the tumor cells. It builds up in these cells and gives off radiation that may kill them. Typically, this medication is given at the same dose every 6 weeks for up to 6 doses. In this trial, researchers want to see if treatment following the first two doses of lutetium 177 Lu PSMA RLT can be delayed until there is evidence of disease activity. This may be an effective way to improve quality of life without decreasing lifespan in patients with advanced prostate cancer.
This description comes directly from the study's public registry record.
Shiva Baghaie, MPH · 773-702-9171 · GUprotocols@alliancenctn.org
Always discuss trial participation with your own doctor first.
| Providence Alaska Medical Center | Anchorage, Alaska, United States | Suspended |
| AIS Cancer Center at San Joaquin Community Hospital | Bakersfield, California, United States | Recruiting |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine, California, United States | Recruiting |
| City of Hope at Irvine Lennar | Irvine, California, United States | Recruiting |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange, California, United States | Recruiting |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| Helen F Graham Cancer Center | Newark, Delaware, United States | Recruiting |
| Medical Oncology Hematology Consultants PA | Newark, Delaware, United States | Recruiting |
| CTCA at Southeastern Regional Medical Center | Newnan, Georgia, United States | Recruiting |
| Kootenai Health - Coeur d'Alene | Coeur d'Alene, Idaho, United States | Recruiting |
| Kootenai Clinic Cancer Services - Post Falls | Post Falls, Idaho, United States | Recruiting |
| Kootenai Clinic Cancer Services - Sandpoint | Sandpoint, Idaho, United States | Recruiting |
+ 90 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07200830